MX342990B - Cristal de compuesto heterociclico fusionado. - Google Patents
Cristal de compuesto heterociclico fusionado.Info
- Publication number
- MX342990B MX342990B MX2013015354A MX2013015354A MX342990B MX 342990 B MX342990 B MX 342990B MX 2013015354 A MX2013015354 A MX 2013015354A MX 2013015354 A MX2013015354 A MX 2013015354A MX 342990 B MX342990 B MX 342990B
- Authority
- MX
- Mexico
- Prior art keywords
- crystal
- heterocyclic compound
- fused heterocyclic
- imidazo
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
La presente invención se refiere a un cristal de 1-etil-7-metil-3-{4-[(3-metil-3H-imidazo[4,5-b]piridin-2-il)oxi]f enil}-1,3-dihidro-2H-imidazo[4,5-b]piridin-2-ona útil como un agente profiláctico o terapéutico para la esquizofrenia y similares, que muestra un patrón de difracción de polvo por rayos X con picos característicos en espaciamientos interplanares (d) de 13,59±0,2 y 6,76±0,2 Angstroms en la difracción de polvo por rayos X.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011138920 | 2011-06-22 | ||
| PCT/JP2012/066461 WO2012176934A1 (en) | 2011-06-22 | 2012-06-21 | Crystal of fused heterocyclic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013015354A MX2013015354A (es) | 2014-02-11 |
| MX342990B true MX342990B (es) | 2016-10-20 |
Family
ID=46551819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013015354A MX342990B (es) | 2011-06-22 | 2012-06-21 | Cristal de compuesto heterociclico fusionado. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9512118B2 (es) |
| EP (1) | EP2723738B1 (es) |
| JP (1) | JP6025757B2 (es) |
| KR (1) | KR20140040777A (es) |
| CN (1) | CN103608348B (es) |
| AR (1) | AR087004A1 (es) |
| AU (1) | AU2012274292B2 (es) |
| BR (1) | BR112013032052A2 (es) |
| CA (1) | CA2839825C (es) |
| CL (1) | CL2013003632A1 (es) |
| CO (1) | CO6862150A2 (es) |
| CR (1) | CR20140033A (es) |
| DO (1) | DOP2013000311A (es) |
| EA (1) | EA026137B1 (es) |
| EC (1) | ECSP14013165A (es) |
| GE (1) | GEP20166475B (es) |
| MA (1) | MA35274B1 (es) |
| MX (1) | MX342990B (es) |
| MY (1) | MY163483A (es) |
| PE (1) | PE20141030A1 (es) |
| TN (1) | TN2013000510A1 (es) |
| TW (1) | TWI570122B (es) |
| UA (1) | UA112082C2 (es) |
| UY (1) | UY34150A (es) |
| WO (1) | WO2012176934A1 (es) |
| ZA (1) | ZA201309611B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5973990B2 (ja) * | 2011-03-16 | 2016-08-23 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| US10851076B2 (en) | 2017-08-10 | 2020-12-01 | Pratt Bethers | Method for purifying crystals using solvent vapors |
| US10960322B2 (en) | 2018-07-02 | 2021-03-30 | Pratt Bethers | Apparatus for purifying crystals using solvent vapors |
| US10308626B1 (en) | 2018-07-02 | 2019-06-04 | Pratt Bethers | Crystal purification in a glass or metal container |
| US20240052227A1 (en) * | 2022-08-12 | 2024-02-15 | Raytheon Company | Water-based polymer network for transpirant cooling applications |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597826A (en) * | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| CA2582479C (en) * | 2004-10-07 | 2011-07-12 | Pfizer Products Inc. | Benzoimidazole derivatives useful as antiproliferative agents |
| AU2006285915B2 (en) | 2005-08-30 | 2011-02-24 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| FI20055498A0 (fi) | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Sulfonamidijohdannaisia |
| US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| CN101384583A (zh) * | 2006-02-15 | 2009-03-11 | 塞诺菲-安万特股份有限公司 | 氮杂环基-取代的芳基二氢异喹啉酮、它们的制备方法和它们作为药物的用途 |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| JP5313883B2 (ja) | 2007-04-18 | 2013-10-09 | キッセイ薬品工業株式会社 | 含窒素縮合環誘導体、それを含有する医薬組成物及びその医薬用途 |
| CA2717529A1 (en) | 2008-03-11 | 2009-09-17 | Cellzome Limited | Sulfonamides as zap-70 inhibitors |
| TW201030001A (en) | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| MY165585A (en) | 2010-06-24 | 2018-04-05 | Takeda Pharmaceuticals Co | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| US9029536B2 (en) | 2010-08-04 | 2015-05-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| EP2604597B1 (en) | 2010-08-10 | 2017-01-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a |
| JP5973990B2 (ja) | 2011-03-16 | 2016-08-23 | 武田薬品工業株式会社 | 縮合複素環化合物 |
-
2012
- 2012-06-20 TW TW101122358A patent/TWI570122B/zh not_active IP Right Cessation
- 2012-06-21 EP EP12738230.7A patent/EP2723738B1/en active Active
- 2012-06-21 MX MX2013015354A patent/MX342990B/es active IP Right Grant
- 2012-06-21 UY UY0001034150A patent/UY34150A/es not_active Application Discontinuation
- 2012-06-21 AR ARP120102205A patent/AR087004A1/es unknown
- 2012-06-21 UA UAA201400581A patent/UA112082C2/uk unknown
- 2012-06-21 KR KR1020137034952A patent/KR20140040777A/ko not_active Application Discontinuation
- 2012-06-21 CN CN201280029988.3A patent/CN103608348B/zh active Active
- 2012-06-21 GE GEAP201213352A patent/GEP20166475B/en unknown
- 2012-06-21 CA CA2839825A patent/CA2839825C/en not_active Expired - Fee Related
- 2012-06-21 BR BR112013032052A patent/BR112013032052A2/pt not_active IP Right Cessation
- 2012-06-21 US US14/125,390 patent/US9512118B2/en active Active
- 2012-06-21 MY MYPI2013004544A patent/MY163483A/en unknown
- 2012-06-21 PE PE2013002859A patent/PE20141030A1/es not_active Application Discontinuation
- 2012-06-21 EA EA201490092A patent/EA026137B1/ru not_active IP Right Cessation
- 2012-06-21 WO PCT/JP2012/066461 patent/WO2012176934A1/en active Application Filing
- 2012-06-21 JP JP2013557956A patent/JP6025757B2/ja active Active
- 2012-06-21 AU AU2012274292A patent/AU2012274292B2/en not_active Ceased
-
2013
- 2013-12-06 TN TNP2013000510A patent/TN2013000510A1/fr unknown
- 2013-12-18 CL CL2013003632A patent/CL2013003632A1/es unknown
- 2013-12-19 ZA ZA2013/09611A patent/ZA201309611B/en unknown
- 2013-12-20 DO DO2013000311A patent/DOP2013000311A/es unknown
-
2014
- 2014-01-20 MA MA36695A patent/MA35274B1/fr unknown
- 2014-01-21 CO CO14010660A patent/CO6862150A2/es not_active Application Discontinuation
- 2014-01-22 EC ECSP14013165 patent/ECSP14013165A/es unknown
- 2014-01-22 CR CR20140033A patent/CR20140033A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY165730A (en) | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | |
| ZA201307783B (en) | Tri-and tetracylic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent | |
| TN2013000510A1 (en) | Crystal of fused heterocyclic compound | |
| IL235819B (en) | Derivatives of [(2-fluoro-3-amino)phenyl]carbonyl-pyrrolo [3,2-b]pyridin-3-yl and a method for their preparation | |
| PH12014501719B1 (en) | Pyridone derivatives | |
| IL230511B (en) | (s)-4-(8-amino-3-(1-but-2-ynoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridin-2- l) Benzamide as a btk inhibitor | |
| IL228239A0 (en) | Derivatives of 4,3-dihydro-pyrrolo[2.1-[a pyrazine-1-ylamine are effective as beta-saccharatase (bace) inhibitors | |
| IL227496B (en) | Pyrazolo[4,3–b]pyridines are converted as drugs | |
| IL222977A (en) | Compounds 5– (Conjugated Phenyl) –3,2,1 – Triazolo [5,4– b] Pyridine Conjugated at Position 3 | |
| NZ594776A (en) | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | |
| ZA201202688B (en) | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders | |
| MX2014002833A (es) | Derivados fungicidas de 3-fenil[(heterociclilmetoxi)imino]metil}-1 ,2,4-oxadiazol-5(4h)-ona sustituidos en 4. | |
| EP2580217A4 (en) | 6- (ETHYNYL-) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| ZA201207550B (en) | Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | |
| HK1139948A1 (en) | Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
| IL201209A0 (en) | Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer | |
| IL221479A0 (en) | Triazolo [4,5-b] pyridin derivatives | |
| GB201107985D0 (en) | Process | |
| MY164138A (en) | Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring | |
| MY162945A (en) | Azole derivative | |
| ZA201308050B (en) | Fe(iii) complexes for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | |
| CO6761387A2 (es) | Compuesto de oxazol[5,4-b]piridin 5-ilo | |
| MY164133A (en) | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring | |
| IL236480B (en) | A process for the preparation of n-oxides of 5-(1-alkylthio)alkyl-pyridine substituted in position 2 | |
| NZ623063A (en) | Antibacterial compounds and methods for use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |